Re-aligning the ASCO and ESMO clinical benefit frameworks for modern cancer therapies

Affiliations

¹ Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, Canada.
² Institute of Cancer Policy, King's College London, London, UK; King's Health Partners Comprehensive Cancer Centre, London, UK.
³ Kingston General Hospital Research Institute, Kingston.
⁴ Department of Oncology, Queen's University, Kingston, Canada; Department of Public Health Sciences, Queen's University, Kingston, Canada. Electronic address: boothc@kgh.kari.net.

Free article

Comment

J C Del Paggio et al. Ann Oncol. 2018.

Free article

. 2018 Mar 1;29(3):773-774.

doi: 10.1093/annonc/mdx721.

¹ Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, Canada.
² Institute of Cancer Policy, King's College London, London, UK; King's Health Partners Comprehensive Cancer Centre, London, UK.
³ Kingston General Hospital Research Institute, Kingston.
⁴ Department of Oncology, Queen's University, Kingston, Canada; Department of Public Health Sciences, Queen's University, Kingston, Canada. Electronic address: boothc@kgh.kari.net.

No abstract available

Comment in

Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'.
Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE. Cherny NI, et al. Ann Oncol. 2018 Mar 1;29(3):774-775. doi: 10.1093/annonc/mdx747. Ann Oncol. 2018. PMID: 29161364 No abstract available.

ESMO-Magnitude of Clinical Benefit Scale version 1.1.
Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE. Cherny NI, et al. Ann Oncol. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310. Ann Oncol. 2017. PMID: 28945867